Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.50 |
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27715158 | 0.93 | ADORA3 (0.45) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL29655156 | 0.91 | ADORA3 (0.50) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL219553 | 0.90 | ADORA3 (0.49) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL27653575 | 0.89 | ADORA3 (0.48) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL30042226 | 0.89 | PI4KA (0.39) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL2761283 | 0.87 | PI4KA (0.47) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| Phosphoric Acid SCHEMBL474409 | 0.86 | ADORA1 (0.48) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL2480947 | 0.86 | PI4KA (0.46) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL2480939 | 0.86 | PI4KA (0.46) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL30211760 | 0.86 | PI4KA (0.46) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117413065-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-117222741-A | Site-specific genomic modification techniques | 北卡罗来纳大学 | 2023-12-12 | — | — | CN | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| CN-114929244-A | Mannose-based mRNA targeted delivery system and application thereof | 深圳市瑞吉生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-20210108252-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | claimed |
| CN-111744019-A | Mannose-based mRNA (messenger ribonucleic acid) targeted delivery system and application thereof | 深圳市瑞吉生物科技有限公司 | 2020-10-09 | — | — | CN | claimed |
| EP-3656872-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2020-05-27 | — | — | EP | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-3387150-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2018-10-17 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| WO-2017098468-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | claimed |
| CN-104870022-A | In vivo production of proteins | modeRNA Therapeutics | 2015-08-26 | — | — | CN | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| CN-103764169-A | Perfluorinated compounds for non-viral transfer of nucleic acids | SCHAEFER KONSTANZE | 2014-04-30 | — | — | CN | claimed |
| CN-103687957-A | Engineered nucleic acids and methods for their use in non-human vertebrates | modeRNA Therapeutics | 2014-03-26 | — | — | CN | claimed |
| WO-2014039809-A2 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-03-13 | — | — | WO | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |
| EP-2547379-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | Fresenius Medical Care Deutschland GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113607-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| CN-101855351-A | Compositions and methods for the identification of inhibitors of retroviral infection | TRANA DISCOVERY | 2010-10-06 | — | — | CN | claimed |